- Diagnostics
- Thursday, 09 Jul 2020
CooperRiis Launches New Insurance Driven Intensive Clinical Program
CooperRiis residential mental health treatment and healing community in Western North Carolina is pleased to introduce their new clinically intensive and insurance-driven CooperRiis at Asheville Program, opening September 1st, 2020. The CooperRiis at Asheville Program offers short-term treatment; 30-90 days, designed to promote stabilization and develop a foundation for a potential next step into its longer-term residential program on The CooperRiis Farm in Mill Spring.
The CooperRiis at Asheville Program integrates clinical services through psychiatry, individual and group therapy, and independent skill and functional recovery programming. The recovery program will benefit individuals in early recovery and individuals experiencing setbacks or recurrent mental health and substance use challenges.
The CooperRiis at Asheville Program treats adults 18 and over who experience mental health diagnoses such as anxiety, major depression, PTSD, bipolar disorder, schizophrenia, personality disorders, and any co-occurring condition related to addiction (dual diagnosis).
The CooperRiis at Asheville Program provides clinical services that will include psychotherapy, psychiatry, experiential group therapy, optimized medication use, psychoeducation, and 24-hour nursing. Evidenced-based group modalities are offered, such as Dialectical Behavioral Therapy (DBT), Acceptance and Commitment Therapy (ACT), Expressive Arts Therapy, and Psychosis Support.
The introduction of this new program is especially relevant today, as the COVID-19's emerging impact on society's mental health has been profound. The CooperRiis commitment to the principles of recovery provides an essential service for people whose emotional well-being has been further compromised by the pandemic.
"CooperRiis believes that with its focused attention, this program can help address the emerging societal complexity of the virus epidemic with this vulnerable population," Eric A. Levine, Ed.D, President and CEO.
Related Industry Updates
Asia Pacific Animal Health Market Outlook, Research, Trends and Forecast up to 2027| Virbac, Elanco, Merck & co
Oct 22, 2020
PSA Test Explained: What It Is, How It Works, and Why It Matters
Mar 27, 2026
Viracor Eurofins Launches Highly Accurate Antibody Tests for Coronavirus (COVID-19) SARS-CoV-2
May 08, 2020
qFIBS Demonstrates Suitability for Nonalcoholic Steatohepatitis (NASH) Assessment in Clinical Trials and Patient Care with Full Quantification of All Crucial Histopathological Features
Nov 11, 2019
Jolly Good and National Center for Cognitive Behavior Therapy and Research Enter Clinical Trial Collaboration for VR Therapeutics
Apr 02, 2020
Dermatologicals Market 2031: Growth Outlook, Key Drivers, and Emerging Opportunities
Nov 20, 2025
Leader of leading Rare Disease Company (CENTOGENE) enters in the Finals of EY Entrepreneur of the Year 2019
Sep 23, 2019